Molly Nozyce, PhD

Department: Neurodevelopmental and Behavior



Dr. Nozyce is the Director of the Division of Developmental Pediatrics. Dr Nozyce is an Associate Professor of Pediatrics at the Albert Einstein College of Medicine.

Education & Training

Undergraduate School:
Hunter College

Graduate School:
New School for Social Research
Yeshiva University, Ferkauf Graduate School of Psychology, PhD


  • Internship: Albert Einstein College of Medicine
  • Developmental-Behavioral Fellowship: Bronx Developmental Center

Honors & Awards


  • Malee KM, Chernoff MC, Nozyce ML, et al; Memory and Executive Functioning Study of the Pediatric HIV/AIDS Cohort Study. Impact of Perinatally Acquired HIV Disease Upon Longitudinal Changes in Memory and Executive Functioning. J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):455-464.
  • Sirois PA, Chernoff MC, Nozyce ML, et al; Memory and Executive Functioning Study of the Pediatric HIV/AIDS Cohort Study. Associations of Memory and Executive Functioning With Academic and Adaptive Functioning Among Youth With Perinatal HIV Exposure and/or Infection. J Pediatric Infect Dis Soc. 2016 Dec;5(suppl 1):S24-S32.
  • Van Dyke RB, Wiznia A, Nozyce M, et al. Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV. Clin Infect Dis. 2016 Jul 1;63(1):133-137.
  • Sirois PA, Aaron L, Nozyce ML, et al; IMPAACTPACTG 219C Team. Stimulant Medications and Cognition, Behavior and Quality of Life in Children and Youth with HIV. Pediatr Infect Dis J. 2016 Jan;35(1):e12-8.
  • Purswani MU; Pediatric HIV/AIDS Cohort Study (PHACS), Wiznia A, Nozyce M, et al. Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. Clin Infect Dis. 2016 Jan 1;62(1):106-114.
  • Nozyce ML, Huo Y, Williams PL, et al; Pediatric HIVAIDS Cohort Study. Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age. Pediatr Infect Dis J. 2014 Nov;33(11):1128-33.
  • Grant R, Nozyce M. Proposed changes to the American Psychiatric Association diagnostic criteria for autism spectrum disorder: implications for young children and their families. Matern Child Health J. 2013 May;17(4):586-92.
  • Sirois PA, Huo Y, Nozyce ML; Pediatric HIVAIDS Cohort Study. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013 Jun;32(6):648-55.
  • Miller TI, Borkowsky W, Nozyce M, et al. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012 May;13(5):264-75.
  • Kapetanovic S, Aaron L, Nozyce ML, et al; Pediatric AIDS Clinical Trials. The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV. AIDS Patient Care STDS. 2009 Nov;23(11):939-47.
  • Sirois PA, Montepiedra G, Nozyce ML; IMPAACT/PACTG 219C Team. Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. J Dev Behav Pediatr. 2009 Oct;30(5):403-12.
  • Nozyce ML, Lee SS, Wiznia A, et al: A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics 2006;117:763-70.
  • Jeremy RJ, Kim S, Nozyce M, et al: Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics 2005;115:380-7.
  • Pearson DA, McGrath NM, Nozyce M, et al: Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatrics 2000;106:E76.
  • Raskino C, Pearson DA, Baker CJ, Lifschitz MH, O'Donnell K, Mintz M, Nozyce M, et al: Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatrics 1999;104:e32.